Canaccord lowered the firm’s price target on Staar Surgical (STAA) to $31 from $41 and keeps a Hold rating on the shares. The firm said Management reiterated FY24 guidance, but with both China and the US businesses missing our estimates, and with management reducing the guidance related to both geographies, they remain cautious on the name.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA: